Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Innovent Announces 100% Response Rate for its CAR-T in Multiple Myeloma

publication date: Dec 11, 2019

Innovent Biologics of Suzhou announced its anti-BCMA CAR-T achieved a 100% response rate in patients with relapsed/refractory multiple myeloma. In addition, 71% of patients had a stringent complete or complete response, and 88% achieved a very good partial response or better. Four of the 17 evaluated patients in the study had relapsed from prior murine CAR-T treatments, implying IBI326 could be a first-line treatment for patients who have relapsed from prior CAR-T infusions. Innovent is developing IBI326 together with Nanjing IASO Bio, an oncology cell therapy company. More details....

Stock Symbol: (HK: 01801)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.